Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Update

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the recipient of a significant growth in short interest in August. As of August 14th, there was short interest totaling 89,867 shares, a growth of 59.5% from the July 30th total of 56,341 shares. Based on an average daily trading volume, of 78,742 shares, the short-interest ratio is presently 1.1 days. Currently, 1.1% of the shares of the company are sold short.

Institutional Investors Weigh In On Lisata Therapeutics

A number of large investors have recently modified their holdings of LSTA. BlackRock Inc. purchased a new stake in Lisata Therapeutics during the 2nd quarter valued at about $1,730,000. GSA Capital Partners LLP purchased a new stake in shares of Lisata Therapeutics in the second quarter valued at approximately $321,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Lisata Therapeutics in the second quarter valued at approximately $157,000. Deltec Asset Management LLC acquired a new stake in shares of Lisata Therapeutics in the first quarter valued at approximately $451,000. Finally, Rangeley Capital LLC purchased a new position in Lisata Therapeutics during the first quarter worth approximately $376,000. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Stock Down 11.8%

Shares of NASDAQ LSTA traded down $0.20 during midday trading on Monday, hitting $1.49. The stock had a trading volume of 242,222 shares, compared to its average volume of 182,003. The stock has a 50 day simple moving average of $2.24 and a 200-day simple moving average of $3.40. The company has a market capitalization of $13.43 million, a PE ratio of -0.91 and a beta of 0.88. Lisata Therapeutics has a 1 year low of $0.99 and a 1 year high of $5.07.

Analyst Ratings Changes

LSTA has been the subject of several recent analyst reports. Weiss Ratings upgraded Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. HC Wainwright lowered Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Finally, Zacks Research raised shares of Lisata Therapeutics to a “hold” rating in a research note on Monday, May 18th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.